CAESER Study Completed
CAESER (an acronym based on the participating sites: Canada, Australia,
Europe, and South Africa) is a clinical trial comparing multiple nucleoside
analogues and loviride, a non-nucleoside reverse transcriptase inhibitor, in
1,892 patients with advanced HIV infection. Initiated in March 1995 and
scheduled to end in March 1997, CAESER was prematurely discontinued based on
recommendations from the July 25, 1996 meeting of the Data and Safety Monitoring
End points in the study were standard clinical criteria: an AIDS-defining opportunistic infection or tumor or death. Results of the study are outlined below.
These results indicate that 3TC added to AZT-containing anti-retroviral regimens is associated with a favorable clinical outcome.
Hasta la vista, ACTG!: ACTG Oncology Committee
Finds New Home at National
Cancer Institute, But Funding
Is Woefully Inadequate
This article was provided by Johns Hopkins AIDS Service. It is a part of the publication Hopkins HIV Report.